(S12) Novel Approved Therapies and the Research Pipeline in Beta Cell Preservation: What's Next in T1D?

Saturday, August 8, 2026

1:00 PM - 1:45 PM ET

CE: .75 CE

Pharmacology Hours: .25 CE

Attend this session to learn more about the evolving care paradigm in T1D, approved therapies to slow disease progression, clinical trial opportunities for individuals with early-stage and clinical diabetes, and the role of the DCES in supporting shared decision making.

Learning Objectives:

At the completion of this activity, participants should be able to:

Describe the natural history of T1D and the role of the immune system in disease progression.
Describe approaches to slow or mitigate the destruction of beta cells in T1D.
Discuss the role of the DCES in shared decision making for people in early stage/stage 3 T1D.

Disclosure(s):

Amara Ogbonnaya, MD: No financial relationships to disclose

Julianne Lally, PA-C, DMSc: No financial relationships to disclose

Primary Presenter(s)

AO

Amara Ogbonnaya, MD

Director, Medical Affairs
Breakthrough T1D

Disclosure(s): No financial relationships to disclose

Co-Presenter(s)

JL

Julianne Lally, PA-C, DMSc

Associate Director, Medical Affairs
Breakthrough T1D

Disclosure(s): No financial relationships to disclose